Clinical and MRI features associated with amyloid positivity in secondary screening for anti-amyloid-β therapy
{{output}}
Introduction: In Japan, confirmatory biomarker testing for Alzheimer's disease (AD) is insurance-covered only when evaluating eligibility for anti-amyloid-β therapies. This study aimed to identify clinical and magnetic resonanc... ...
